This growth comes on the back of a steady market performance from 2017 to 2022, where the injection pen sector achieved a ...
California made a big bet on producing its own insulin. There’s no ‘date certain’ for delivery
California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.
Why it matters: More than 3.5 million Californians have diabetes, and insulin is a life-saving part of their disease ...
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj ... Both a 3-mL ...
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
Saudi Gazette on MSN12d
Saudi Arabia inaugurates first local insulin manufacturing facility, advancing healthcare self-sufficiencyIn a landmark moment for Saudi Arabia’s healthcare sector, the Kingdom inaugurated its first local insulin manufacturing facility, a key milestone in advancing pharmaceutical self-sufficiency under ...
While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...
The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback